Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show

Gilead’s remdesivir shows some benefit in patients with moderate Covid-19, new data show

Source: 
Stat
snippet: 

Remdesivir, the drug developed as a treatment for Covid-19 by Gilead Sciences, helped patients with “moderate” disease recover more quickly when they received it for five days, but the benefit was not statistically significant when given for 10 days, the company said Monday.